Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines
Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The lipid nanoparticle (LNP) delivery vehicles have inherent immunostimulatory properties that can induce adverse events such as allergic reactions.
Now, Ronald Levy and colleagues from Stanford University in California have developed an alternative approach that uses a novel delivery vehicle called Charge-Altering Releasable Transporters (CARTs).
“Using these inherently nonimmunogenic vehicles, we are able to tailor the vaccine immunogenicity by the inclusion of co-formulated adjuvants such as oligonucleotides with CpG motifs,” they write.

Related Keywords

Stanford University ,California ,United States ,Ronald Levy ,Sally Robertson ,Charge Altering Releasable Transporters ,Sars ,Ars Cov 2 ,Ce2 ,Ngiotensin ,Ngiotensin Converting Enzyme 2 ,Antibodies ,Ntibody ,D4 ,Fell ,Coronavirus ,Coronavirus Disease Covid 19 ,Pg ,Nzyme ,Immunization ,N Vivo ,Anoparticle ,Anoparticles ,Oligonucleotides ,Protein ,Eceptor ,Espiratory ,Na ,Evere Acute Respiratory ,Evere Acute Respiratory Syndrome ,Spike Protein ,Yndrome ,Vaccine ,Virus ,ஸ்டான்போர்ட் பல்கலைக்கழகம் ,கலிஃபோர்னியா ,ஒன்றுபட்டது மாநிலங்களில் ,ரொனால்ட் வசூல் செய்தல் ,சாலி ராபர்ட்சன் ,சர்ச் ,டி4 ,பக் ,நா ,